Why does the Wegovy pill need SNAC?
Your stomach’s job is to digest proteins. Semaglutide is a protein — a small one built from 31 building blocks called amino acids. Without protection, your stomach would break a semaglutide tablet down before any of it reached your blood.
SNAC is short for salcaprozate sodium. Novo Nordisk developed the Wegovy pill and Rybelsus tablet using SNAC technology, which was created by a company called Emisphere Technologies.
SNAC is central to how Wegovy pills work. It shields semaglutide from your stomach’s digestive enzymes. SNAC then helps the medicine pass through the cells lining your stomach, so more of it can be absorbed into your bloodstream.
Without SNAC, oral absorption would be close to zero. Even with it, only around 0.8% of each dose gets through. That is unusually low for a medicine and would be a serious problem for most drugs. This is why the Wegovy pill contains a higher dose of semaglutide than the injection.
How does SNAC protect semaglutide from stomach acid?
Your stomach uses its acid with an enzyme called pepsin to break proteins apart within minutes. SNAC neutralises both in just a tiny area right around the dissolving tablet, a few millimetres wide. A 2018 study confirmed that this concentrated zone is strong enough to shut pepsin down completely. It gives semaglutide enough time to reach the stomach wall.
Everything else digests normally. SNAC’s effect is more like a chemical shield around the tablet rather than an antacid for the whole stomach.
How does SNAC help semaglutide cross the stomach wall?
Surviving the acid is only half the problem. Semaglutide still has to get through the stomach wall, and the outer layer of each stomach cell blocks it.
SNAC works on stomach cells, which is why the Wegovy pill is absorbed in the stomach rather than the intestine. SNAC helps semaglutide pass through the cells of the stomach lining, in a process known as transcellular absorption. A 2025 study compared the process to quicksand, allowing the cells to be more permeable to the medication.
Semaglutide passes directly through the cells without impacting the surrounding ones. The effect wears off within about 30 minutes.
Why do the dosing rules matter for SNAC?
SNAC only works when it stays concentrated in one spot, right around the dissolving tablet. Dilute it, and the protection falls apart. Stomach acid takes over again and destroys semaglutide before your body can absorb it.
Eating before the tablet has dissolved floods your stomach with bulk that scatters SNAC away from where it needs to be. The FDA tested oral semaglutide taken with food. Absorption dropped to near zero in over half of the participants.
That is why you can’t eat after the Wegovy pill for at least 30 minutes, and why only a small amount of water can be taken. Any more than 120mL water and you risk diluting SNAC, which in turn reduces how much of the medication is absorbed. Once the concentration drops too far, semaglutide cannot cross the stomach lining.
Crushing, chewing, breaking the tablet in half or dissolving it in water have the same effect. SNAC needs to dissolve gradually in one spot against the stomach wall. Spreading it across the whole stomach stops it from working. Always swallow the tablet whole.
The dosing rules for oral semaglutide may seem strict, but each one protects the conditions SNAC needs to do its job.
Is SNAC safe?
Prescribers have been using medicines containing SNAC for over five years. Rybelsus was the first FDA-approved oral GLP-1 receptor agonist that used SNAC technology. It launched in 2019 for type 2 diabetes. Both clinical trial and real-world data back its safety and effectiveness.
The same technology now underpins the oral Wegovy weight loss medication. Wegovy helps with obesity management, which in turn reduces the risk of weight-related health problems in adults with obesity when combined with a balanced diet and increased physical activity.
Common side effects of treatment include nausea, stomach discomfort, and reduced appetite. Symptoms come from the active ingredient, semaglutide. SNAC is not the cause.
One question we hear often is whether SNAC affects other medicines you might be taking. The FDA clinical pharmacology review tested it alongside a range of commonly prescribed drugs. In the studies reviewed, SNAC did not meaningfully change how the body absorbed or processed any of those drugs. Wegovy pill drug interactions are driven by semaglutide, mainly through delayed stomach emptying, not by SNAC.
One safety consideration does apply to breastfeeding. A Novo Nordisk clinical study confirmed that SNAC passes into human breast milk. We do not yet know what effect this could have on a breastfed baby.
The prescribing label advises against taking oral semaglutide while breastfeeding. Wegovy pill and breastfeeding is explicitly called out in the Patient Information Leaflet as a .
The Wegovy pill uses the same SNAC technology as Rybelsus. The semaglutide strength differs: 25 mg for long-term body weight management versus 14 mg for type 2 diabetes. In a Wegovy pill vs Rybelsus comparison, the absorption system is identical. The doses and what each tablet treats are not.
When should I see a doctor?
Most side effects from oral semaglutide are mild and settle as your body adjusts. The table below shows who to contact depending on your symptoms.
| Who to contact | When |
| Our clinical team | Questions about whether your dosing routine is affecting how well the tablet worksAdvice on whether to stay on your current dose or step upMild nausea, stomach discomfort, or changes to appetite after taking the tablet |
| Your GP or NHS 111 | Persistent throat discomfort or difficulty swallowing that does not settle within a few daysYou have been vomiting for more than 6 hours and are struggling to keep fluids downA lump in your neck or new hoarseness that does not go awayPain in the upper right side of your abdomen or yellowing of the skin or eyesChanges to your vision – this may be a sign of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) |
| 999 or A&EStop taking your tablet | Severe abdominal pain that spreads to your back and does not ease (possible sign of pancreatitis)Signs of a severe allergic reaction: swelling of the face, lips, or throat, difficulty breathing, or a rapid heartbeat. Dial 999 straightawaySevere dehydration with dizziness, confusion, dark urine, or unable to keep any fluids down |
These symptoms are not specific to SNAC, but they can occur with semaglutide treatment and need prompt medical attention.
Key takeaways
- Without the SNAC absorption enhancer, semaglutide would not exist in tablet form.
- SNAC neutralises stomach acid in a tiny zone around the tablet. SNAC helps your body absorb semaglutide through the lining of the stomach. It works for a short time after the tablet dissolves, helping more of the medicine pass into the bloodstream before the stomach returns to its usual state.
- Every dosing rule protects SNAC concentration. Food, too much water, or crushing the tablet all dilute it. An empty stomach and fasting window is necessary for semaglutide to absorb.
- No effect on other medicines. One flag: SNAC passes into breast milk, so oral semaglutide is not recommended while breastfeeding.
- Wegovy and Rybelsus oral medications use the same SNAC at the same dose. Only the semaglutide strength and what each tablet is licensed for differ.
References
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist, Science Translational Medicine, 2018 [Accessed 24 May 2026]
Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs, Nature Communications, 2025 [Accessed 24 May 2026]
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders, 2022 [Accessed 24 May 2026]
Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience, Clinical Diabetes, 2024 [Accessed 24 May 2026]
FDA NDA 213051 Clinical Pharmacology Review: Oral Semaglutide, US Food and Drug Administration, 2019 [Accessed 24 May 2026]
A trial investigating semaglutide and SNAC concentrations in breastmilk (NCT04817644), ClinicalTrials.gov, 2021–2023 [Accessed 24 May 2026]
Authored by Shereen Amin
Pharmacist Independent Prescriber & Medical Writer
GPhC: 2073003
Shereen is a Pharmacist Independent Prescriber and medical writer with over ten years' experience across NHS primary care, digital health and specialist services. She writes evidence-based health content for Simple Online Pharmacy, turning complex clinical information into guidance patients can actually use.
Medically Reviewed by Zahra Qureshi
Senior Pharmacist
GPhC: 2216331
Zahra began her pharmacy career in community pharmacy, building a strong foundation in patient care and medication safety. She joined Simple Online Pharmacy as a locum pharmacist and quickly progressed to a senior role, supporting the pharmacy and operations teams. Zahra is passionate about ensuring patient guidance is safe, clinically sound, and easy to understand, making a positive difference to patients’ lives.
